ACAD (ACADIA Pharmaceuticals) Cyclically Adjusted PS Ratio: (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ACAD ACADIA Pharmaceuticals Inc ACAD
80 GF Score
Price $29.22
GF Value $24.89
Valuation Modestly Overvalued
! 10 Warning Signs
View Full Analysis

What is ACADIA Pharmaceuticals Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


ACADIA Pharmaceuticals  (NAS:ACAD) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


ACADIA Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms


ACADIA Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for ACADIA Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACADIA Pharmaceuticals Cyclically Adjusted PS Ratio Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.59 7.52 11.65 5.90 7.60

ACADIA Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.47 6.20 7.60 6.10 6.54

ACAD vs LEGN, TNGX, CAI: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, ACADIA Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ACADIA Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where ACADIA Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


ACAD
80GF Score
ACADIA Pharmaceuticals Inc ACAD
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACADIA Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

ACADIA Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, ACADIA Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.782/333.9520*333.9520
=1.782

Current CPI (Jun. 2026) = 333.9520.

ACADIA Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.045 241.428 0.062
201612 0.099 241.432 0.137
201703 0.126 243.801 0.173
201706 0.250 244.955 0.341
201709 0.290 246.819 0.392
201712 0.351 246.524 0.475
201803 0.392 249.554 0.525
201806 0.457 251.989 0.606
201809 0.466 252.439 0.616
201812 0.452 251.233 0.601
201903 0.437 254.202 0.574
201906 0.577 256.143 0.752
201909 0.648 256.759 0.843
201912 0.636 256.974 0.827
202003 0.580 258.115 0.750
202006 0.703 257.797 0.911
202009 0.763 260.280 0.979
202012 0.760 260.474 0.974
202103 0.666 264.877 0.840
202106 0.718 271.696 0.883
202109 0.819 274.310 0.997
202112 0.802 278.802 0.961
202203 0.716 287.504 0.832
202206 0.832 296.311 0.938
202209 0.808 296.808 0.909
202212 0.843 296.797 0.949
202303 0.730 301.836 0.808
202306 1.001 305.109 1.096
202309 1.289 307.789 1.399
202312 1.402 306.746 1.526
202403 1.235 312.332 1.320
202406 1.456 314.175 1.548
202409 1.507 315.301 1.596
202412 1.554 315.605 1.644
202503 1.457 319.799 1.521
202506 1.568 322.561 1.623
202509 1.633 324.800 1.679
202512 1.649 324.054 1.699
202603 1.552 330.213 1.570
202606 1.782 333.952 1.782

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is ACADIA Pharmaceuticals (ACAD) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued. The current stock price of $29.22 is trading 17.4% above its estimated GF Value™ of $24.89. GuruFocus considers ACADIA Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for ACAD:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: $24.89 vs. price of $29.22 (17.4% above fair value)
  • GF Score™: 80/100 with 10 warning signs

No single metric tells the full story. See the ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ACADIA Pharmaceuticals Business Description

Other Exchanges ACAD:MexicoDR6:Germany
Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
80GF Score

Get the complete analysis for ACAD

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.22
Price
$24.89
GF Value